// App-Quantinova.ai

3087 : An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Alessandro Vannucchi

  • Adam J. Mead

  • Regina Garcia-Delgado

  • Andrzej Pluta

  • Hope Qamoos

  • Anne Uyei

  • Damaj Gandhi Laurent

  • Haifa K Al-Ali

Medical Centers

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Florence, Florence, Italy

  • Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

  • Servicio de Oncologia, Hospital Virgen de la Victoria, Malaga, Spain

  • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza,Brzozów,Poland

  • Kartos Therapeutics, Inc., Redwood City, CA

  • CHU Caen, Caen, France

  • Department of Hematology and Oncology, University of Halle, Halle, Germany

Locations

  • United States

  • Italy

  • United Kingdom

  • Spain

  • Poland

  • France

  • Germany

Companies

  • Kartos Therapeutics,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • Mouse double minute 2 homolog

  • Tumor protein p53

Drug/Treatment

  • Ruxolitinib phosphate

  • KRT-232

  • TP53

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04485260

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved